Bruce Moore, former vice president of marketing for the Diasonicsultrasound division, was named president of the division lastmonth. He was previously vice president of marketing for DiasonicsMRI. Moore returned to Diasonics--along with president and
Bruce Moore, former vice president of marketing for the Diasonicsultrasound division, was named president of the division lastmonth. He was previously vice president of marketing for DiasonicsMRI.
Moore returned to Diasonics--along with president and COO RoderickA. Young--following Toshiba's acquisition of the magnetic resonanceimaging business (SCAN 8/1/90). Young had initially taken on directresponsibility for the Diasonics ultrasound business.
A replacement for Moore as vice president of marketing forthe ultrasound division assumed his new responsibilities thisweek. William E. Richardson was formerly general manager of theinformation systems division of ADAC Laboratories.
While Diasonics improved the profitability of its businessessince the sale of the MRI division, ultrasound continued to lagbehind expectations last year (SCAN 2/13/91). Sales of the vendor'sSpectra high-end radiology ultrasound scanner should pick up nowthat a new color-flow Doppler architecture has been fully implemented,Moore said.
The vendor introduced its Spectra Plus color architecture atthe 1990 Radiological Society of North America meeting but didnot finish software revisions and begin demonstrating the packagein the field until last month, he said.
Diasonics' international ultrasound sales, through its Swisssubsidiary Sonotron, were strong last year despite the fact thatSpectra sales had not yet kicked in. Sonotron is expected to launcha Spectra product tailored to Europe this year.
Ultrasound sales should also get a boost from the incorporationof Diasonics' intravascular ultrasound system (IVUS) as an optionon Spectra. IVUS had been sold previously only as a stand-alonedevice. The IVUS option on Spectra will cost about $40,000, orless than half of what the stand-alone unit costs, Moore said.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.